ArticleEMBO reports2017
Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in EMBO reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- The metabolic profiles of cancer stem cells.Stem cell research & therapy · 2026Review
- Augment proteasome inhibitor efficacy activates CD8Cell reports. Medicine · 2025Article
- Therapeutic advances in the targeting of ROR1 in hematological cancers.Cell death discovery · 2024Review
- Marizomib (Salinosporamide A) Promotes Apoptosis in A375 and G361 Melanoma Cancer Cells.Marine drugs · 2024Article
- Article
- AMPK-HIF-1α signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth.Journal of experimental & clinical cancer research : CR · 2023Article
- Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.Current oncology (Toronto, Ont.) · 2023Review
- Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth.Cell death & disease · 2022Article
- Pharmacological targeting of endoplasmic reticulum stress in disease.Nature reviews. Drug discovery · 2022Review
- The Role of Protein S-Nitrosylation in Protein Misfolding-Associated Diseases.Life (Basel, Switzerland) · 2021Review
- The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.Molecular neurobiology · 2021Review
- Effective Drug Concentration and Selectivity Depends on Fraction of Primitive Cells.International journal of molecular sciences · 2021Article
- Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome.Oncology reports · 2021Article
- The role of E3 ubiquitin ligases in the development and progression of glioblastoma.Cell death and differentiation · 2021Review
- Review
- Post-translational Modifications of the Protein Termini.Frontiers in cell and developmental biology · 2021Review
- Adenovirus infection promotes the formation of glioma stem cells from glioblastoma cells through the TLR9/NEAT1/STAT3 pathway.Cell communication and signaling : CCS · 2020Article
- Review
- Activation of JNK and p38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.Theranostics · 2020Article
- An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.Molecular cancer research : MCR · 2019Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
19 authors at 5 institutions in 3 countries.
Young Dong YooProtein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
Dae-Hee LeeBrain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul, Korea.
Hyunjoo Cha-MolstadWorld Class Institute, Anticancer Agents Research Center, Korea Research Institute of Bioscience & Biotechnology, Ochang Cheongwon, Korea.
Hyungsin KimDepartment of Neurosurgery, College of Medicine Korea University Medical Center Korea University, Seoul, Korea.
Su Ran MunProtein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
Changhoon JiProtein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
Seong Hye ParkBrain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul, Korea.
Ki Sa SungProtein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
Seung Ah ChoiDivision of Pediatric Neurosurgery, College of Medicine, Seoul National University, Seoul, Korea.
Joonsung HwangDepartment of Neurosurgery, College of Medicine Korea University Medical Center Korea University, Seoul, Korea.
Deric M ParkDepartment of Neurosurgery, University of Virginia School of Medicine, Charlottesville, VA, USA.
Seung-Ki KimDivision of Pediatric Neurosurgery, College of Medicine, Seoul National University, Seoul, Korea.
Kyung-Jae ParkDepartment of Neurosurgery, College of Medicine Korea University Medical Center Korea University, Seoul, Korea.
Shin-Hyuk KangDepartment of Neurosurgery, College of Medicine Korea University Medical Center Korea University, Seoul, Korea.
Sang Cheul OhBrain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul, Korea.
Aaron CiechanoverProtein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea.
Yong J LeeDepartments of Surgery and Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA yok5@snu.ac.kr bykim@kribb.re.kr leeyj@upmc.edu.ORCID 0000-0001-5914-8489
Bo Yeon KimDepartment of Neurosurgery, College of Medicine Korea University Medical Center Korea University, Seoul, Korea yok5@snu.ac.kr bykim@kribb.re.kr leeyj@upmc.edu.
Yong Tae KwonProtein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea yok5@snu.ac.kr bykim@kribb.re.kr leeyj@upmc.edu.ORCID 0000-0002-8115-3150
Seoul National University · KRKorea University Medical Center · KRKorea University · KRUniversity of Pittsburgh · USUniversity of Virginia · US
Funding
Multimodality approach to hepatic colorectal metastasesR01CA140554 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARTLETT, DAVID L, LEE, YONG J · 2010 to 2014
$1.6MNCI NIH HHS R01 CA140554
Abstract
Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC
Indexed as
AnimalsAntineoplastic AgentsApoptosisBiomarkersCell Line, TumorCell SurvivalDisease Models, AnimalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGliomaHumansJNK Mitogen-Activated Protein KinasesMiceModels, BiologicalNeoplastic Stem CellsNF-kappa BAntineoplastic AgentsBiomarkersJNK Mitogen-Activated Protein KinasesNF-kappa BProteasome Endopeptidase ComplexProteasome Inhibitorsapoptosisc‐Jun N‐terminal kinaseglioma stem cellsproteasome inhibitorsubiquitin proteasome system
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.